Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clopidogrel vs Ticlopidine Safety in PAD
NCT00862420Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2009
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of clopidogrel in Peripheral Arterial Disease (PAD) (2 arms), sponsored by Sanofi. Primary endpoint: Safety events of interest at 12 weeks. Started Feb 2009; status: completed.
02
Drugs
clopidogrel
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT00862420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00862420.